Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$33.34
+1.1%
$34.50
$21.62
$39.54
$6.33B1.152.45 million shs2.05 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$267.56
-2.1%
$312.42
$200.63
$377.46
$5.94B-0.91384,017 shs352,361 shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
$75.06
+3.3%
$64.57
$11.39
$75.60
$5.89B0.21.30 million shs861,523 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-1.48%-7.29%-9.53%+13.91%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-8.04%-16.37%-20.42%+13.83%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%+0.44%
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.00%+5.26%+15.87%+10.45%+495.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.5931 of 5 stars
4.52.00.03.93.33.30.6
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.4663 of 5 stars
4.50.00.04.62.64.20.6
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
1.8315 of 5 stars
2.61.00.00.04.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.92
Moderate Buy$57.0971.24% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.90
Moderate Buy$416.3355.60% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.11
Buy$81.508.58% Upside

Current Analyst Ratings Breakdown

Latest TARO, MDGL, BBIO, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$441.00 ➝ $458.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$422.00 ➝ $460.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$394.00 ➝ $420.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $72.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$75.00 ➝ $85.00
4/28/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
4/28/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$100.00
4/24/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.00
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$127.42M49.69N/AN/A($7.71) per share-4.32
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$317.38M18.72N/AN/A$20.53 per share13.03
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
Verona Pharma plc stock logo
VRNA
Verona Pharma
$118.54M51.34N/AN/A$3.10 per share24.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%8/7/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%8/6/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$2.00N/A2,502.00N/AN/A-79.54%-43.49%N/A

Latest TARO, MDGL, BBIO, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million
4/29/2025Q1 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million
4/29/2025Q1 2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
2/26/2025Q4 2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
4.67
4.67
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.15
5.98
5.93
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.93
13.03
12.88

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
91.40%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400189.88 million143.29 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million16.84 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
3081.08 million76.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$33.34 +0.37 (+1.12%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$34.65 +1.31 (+3.93%)
As of 05/23/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$267.56 -5.79 (-2.12%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$266.80 -0.76 (-0.29%)
As of 05/23/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Verona Pharma stock logo

Verona Pharma NASDAQ:VRNA

$75.06 +2.37 (+3.26%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$73.53 -1.53 (-2.04%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.